Related Experiment Video
Updated: Jun 20, 2025
09:06
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.3K
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
Rafael Zubirán1, Edward B Neufeld1, Amaury Dasseux1
1Lipoprotein Metabolism Laboratory, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Cardiology and Therapy
|July 20, 2024
Summary
Inflammation drives residual risk in atherosclerotic cardiovascular disease (ASCVD) even with cholesterol therapy. Targeting inflammation offers new therapeutic strategies for ASCVD patients.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a primary cause of death globally.
- Current therapies targeting low-density lipoprotein cholesterol (LDL-C) reduce ASCVD risk but do not eliminate it.
- Inflammation plays a significant role in the remaining, or residual, ASCVD risk.
Purpose of the Study:
- To review the role of inflammation in ASCVD progression and plaque stability.
- To explore inflammatory biomarkers, such as high-sensitivity C-reactive protein (hsCRP), for identifying residual risk.
- To propose novel therapeutic strategies targeting inflammation in ASCVD.
Main Methods:
- Literature review of studies on inflammation and ASCVD.
- Analysis of the biological mechanisms linking inflammation to atherosclerosis.
- Evaluation of current and potential future therapeutic targets for inflammation.
Main Results:
- Inflammation contributes to the development and instability of atherosclerotic plaques.
- Biomarkers like hsCRP can identify patients with an inflammatory ASCVD risk phenotype.
- Targeting inflammatory pathways presents a promising avenue for improving ASCVD outcomes.
Conclusions:
- Inflammation is a critical factor in residual ASCVD risk.
- hsCRP and other inflammatory markers can guide risk stratification and treatment.
- Developing inflammation-targeted therapies is essential for a new paradigm in ASCVD management.
Related Concept Videos
01:38Inflammation
53.3K
Overview
53.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
127
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
127
01:28Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
510
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
510